298 related articles for article (PubMed ID: 23458227)
1. Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl.
Perelman M; Fisher AN; Smith A; Knight A
Int J Clin Pharmacol Ther; 2013 May; 51(5):349-56. PubMed ID: 23458227
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic meta-analysis of intranasal fentanyl spray as a means to enrich pharmacokinetic information for patients with cancer breakthrough pain.
Kaessner N; Nave R; Roepcke S; Facius A; Lahu G
Int J Clin Pharmacol Ther; 2012 Sep; 50(9):665-77. PubMed ID: 22784611
[TBL] [Abstract][Full Text] [Related]
3. Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study.
Parikh N; Goskonda V; Chavan A; Dillaha L
Clin Ther; 2013 Mar; 35(3):236-43. PubMed ID: 23497761
[TBL] [Abstract][Full Text] [Related]
4. Single-dose and multi-dose delivery systems for intranasal fentanyl spray are bioequivalent as demonstrated in a replicate pharmacokinetic study.
Nave R; Connolly SM; Popper L; Lahu G; Schmitt H
Int J Clin Pharmacol Ther; 2012 Oct; 50(10):751-9. PubMed ID: 22943926
[TBL] [Abstract][Full Text] [Related]
5. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
[TBL] [Abstract][Full Text] [Related]
6. An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects.
Plock N; Facius A; Hartmann L; Baumann S; Nave R
Int J Clin Pharmacol Ther; 2013 Jun; 51(6):495-508. PubMed ID: 23611571
[TBL] [Abstract][Full Text] [Related]
7. A pharmacokinetic assessment of an alternate titration strategy for fentanyl pectin nasal spray.
Perelman M; Knight A
Int J Clin Pharmacol Ther; 2013 Dec; 51(12):942-7. PubMed ID: 24120713
[TBL] [Abstract][Full Text] [Related]
8. Effect of dosing interval on pharmacokinetics of fentanyl pectin nasal spray from a crossover study.
Chen C; Bujanover S; Gupta A
J Opioid Manag; 2015; 11(2):139-46. PubMed ID: 25901479
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 - 800 µg in healthy volunteers.
Fisher A; Watling M; Smith A; Knight A
Int J Clin Pharmacol Ther; 2010 Dec; 48(12):860-7. PubMed ID: 21084042
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188.
Fisher A; Watling M; Smith A; Knight A
Int J Clin Pharmacol Ther; 2010 Feb; 48(2):138-45. PubMed ID: 20137766
[TBL] [Abstract][Full Text] [Related]
11. One-week use of oxymetazoline nasal spray in patients with rhinitis medicamentosa 1 year after treatment.
Graf P; Hallén H
ORL J Otorhinolaryngol Relat Spec; 1997; 59(1):39-44. PubMed ID: 9104748
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery.
Foster D; Upton R; Christrup L; Popper L
Ann Pharmacother; 2008 Oct; 42(10):1380-7. PubMed ID: 18728103
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers.
Darwish M; Kirby M; Robertson P; Tracewell W; Jiang JG
Clin Ther; 2006 May; 28(5):707-14. PubMed ID: 16861092
[TBL] [Abstract][Full Text] [Related]
14. A study of the effect of nasal steroid sprays in perennial allergic rhinitis patients with rhinitis medicamentosa.
Ferguson BJ; Paramaesvaran S; Rubinstein E
Otolaryngol Head Neck Surg; 2001 Sep; 125(3):253-60. PubMed ID: 11555762
[TBL] [Abstract][Full Text] [Related]
15. [Investigation of the effect of oxymetazoline on the duration of rhinitis. results of a placebo-controlled double-blind study in patients with acute rhinitis].
Reinecke S; Tschaikin M
MMW Fortschr Med; 2005 Oct; 147 Suppl 3():113-8. PubMed ID: 16261947
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
[TBL] [Abstract][Full Text] [Related]
17. Intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
Dietrich E; Gums JG
Ann Pharmacother; 2012 Oct; 46(10):1382-91. PubMed ID: 23012382
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and dose proportionality of fentanyl sublingual spray: a single-dose 5-way crossover study.
Parikh N; Goskonda V; Chavan A; Dillaha L
Clin Drug Investig; 2013 Jun; 33(6):391-400. PubMed ID: 23605506
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study.
Fallon M; Reale C; Davies A; Lux AE; Kumar K; Stachowiak A; Galvez R;
J Support Oncol; 2011; 9(6):224-31. PubMed ID: 22055892
[TBL] [Abstract][Full Text] [Related]
20. Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.
Mercadante S; Prestia G; Adile C; Casuccio A
J Pain; 2014 Jun; 15(6):602-7. PubMed ID: 24561001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
